Moderna Stock Is Sliding Monday: What's Going On?

Core Insights - Moderna Inc's stock is experiencing a significant decline due to recent clinical setbacks overshadowing positive developments in its pipeline [1][2] - The company announced the dosing of the first patient in a Phase 1/2 study for mRNA-2808, a T-cell engager for multiple myeloma, but this was not enough to support the stock price [1] - The stock price fell 8.49% to $24.86, reflecting ongoing investor concerns [4] Clinical Developments - Moderna halted the Phase 3 trial for its cytomegalovirus vaccine, mRNA-1647, after it failed to meet its primary efficacy endpoint, leading to negative analyst reactions [2] - Analysts have adjusted their price targets, with UBS cutting its target to $40 and JPMorgan setting a target of $25 while maintaining an Underweight rating [2] Financial Outlook - The upcoming earnings report is anticipated, with consensus estimates projecting a quarterly loss of approximately $2.15 per share on revenue of about $860 million [3] - Current momentum score for Moderna is 12.67, indicating a negative price trend for the medium and long term [3]